68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)

Inclusion Criteria:

1. Female with age ≥ 18 years,

2. Patients with previously untreated, non-metastatic, centrally confirmed TNBC (stageT1c N1-2 or T2-4 N0-2 per AJCC) for whom a neoadjuvant treatment with chemotherapy +pembrolizumab is the recommended option as standard of care,

3. Patients with measurable targets according to RECIST/PERCIST criteria,

4. Patients without distant metastasis based on staging 18F-FDG PET/CT,

5. Patients with tumor tissue available,

6. Patients who provided a signed written informed consent,

7. Patient ability to comply with protocol requirements,

8. Patients covered by a health insurance system.

Exclusion Criteria:

1. Pregnant and lactating women,

2. Patients with prior anti-PD(L)1 immunotherapy,

3. Patients with any contra-indication to chemo-immunotherapy standard of care therapy,per investigator assessment,

4. Patients with altered mental status or psychiatric disorder that, in the opinion ofthe investigator, would preclude a valid patient informed consent,

5. Patients who have difficulty undergoing trial procedures for geographic, social orpsychological reasons,

6. Patients who are not affiliated to a social security system, or who are deprived ofliberty, or under guardianship.

7. Person deprived of liberty or under guardianship